Clinical and Cardiac Safety of Long-term Levofloxacin in Children Treated for Multidrug-resistant Tuberculosis
Garcia-Prats AJ, Draper HR, Finlayson H, Winckler J, Burger A, Fourie B, Thee S, Hesseling AC, et al. (9 authors)
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2018-11
Abstract
Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.
MeSH terms
- Heart
- Humans
- Tuberculosis, Multidrug-Resistant
- Antitubercular Agents
- Prospective Studies
- Time Factors
- Adolescent
- Child
- Child, Preschool
- South Africa
- Female
- Male
- Levofloxacin